Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $118.6 million.

  • Madrigal Pharmaceuticals' Total Non-Current Liabilities rose 191.99% to $345.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.3 million, marking a year-over-year increase of 191.99%. This contributed to the annual value of $118.6 million for FY2024, which is 1.65% up from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Total Non-Current Liabilities stood at $118.6 million, which was up 1.65% from $116.7 million recorded in FY2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Total Non-Current Liabilities peaked at $118.6 million during FY2024, and registered a low of $387,000 during FY2021.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Total Non-Current Liabilities value was $116.7 million (recorded in 2023), while the average stood at $94.8 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Total Non-Current Liabilities decreased by 17.31% in 2021, and later spiked by 12,636.18% in 2022.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Total Non-Current Liabilities stood at $468,000 in 2020, then fell by 17.31% to $387,000 in 2021, then surged by 12,636.18% to $49.3 million in 2022, then spiked by 136.70% to $116.7 million in 2023, then grew by 1.65% to $118.6 million in 2024.